Health
Excel
Eye Diseases Dataset – Vision & Ophthalmic Conditions Database
Eye Diseases Dataset
The Eye Diseases Dataset is a structured medical database containing a comprehensive list of conditions affecting the eyes and visual system.
Eye diseases can impact vision quality and overall eye health, ranging from common conditions like conjunctivitis to serious disorders such as glaucoma and macular degeneration. This dataset provides organised information to support medical research, healthcare analytics, and application development.
Each record includes key clinical details such as disease descriptions, affected eye structures, common symptoms, severity levels, and treatment approaches.
The dataset has been cleaned and structured for easy integration into spreadsheets, databases, and analytical tools.
It is ideal for ophthalmology research, healthcare developers, educators, and data scientists working with eye health data.
Dataset Contents
The dataset includes fields such as:
- Disease / Condition Name
- Description
- Affected Area (Cornea, Retina, Optic Nerve, Lens, etc.)
- Common Symptoms
- Severity Level
- Disease Category
- Risk Factors
- Treatment / Management
Example Conditions Included
- Cataracts
- Glaucoma
- Age-Related Macular Degeneration (AMD)
- Diabetic Retinopathy
- Conjunctivitis (Pink Eye)
- Dry Eye Syndrome
- Retinal Detachment
- Keratitis
- Uveitis
- Optic Neuritis
...and many more eye and vision-related conditions.
Data Preview
12 columns
25 rows shown
| No. | Disease Name | Category | Primary Cause / Etiology | Prevalence | Age of Onset | Key Symptoms | Affected Organ(s) | Diagnostic Method | Treatment Approach | Prognosis | ICD-10 Code | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ▸ Eyelid, Lacrimal System & Ocular Surface Disorders | |||||||||||
| 2 | 1 | Blepharitis (Anterior) | Eyelid, Lacrimal System & Ocular Surface Disorders | Chronic inflammation of the anterior eyelid margin involving lash follicles and glands of Zeis and Moll. Two main subtypes: staphylococcal (bacterial colonization, especially S. aureus and S. epidermidis producing exotoxins and lipases) and seborrheic (associated with seborrheic dermatitis and Malassezia species). Demodex mite infestation (D. folliculorum and D. brevis) increasingly recognized as contributor in 45-80% of blepharitis patients. Biofilm formation on lid margin perpetuates chronic inflammation. Often coexists with posterior blepharitis and dry eye disease. | One of the most common ocular conditions; estimated to affect 37-47% of all ophthalmology patients. Prevalence increases with age. Both sexes equally affected. Chronic relapsing condition present in up to 30% of general population. More common in patients with rosacea and seborrheic dermatitis. | Can occur at any age; prevalence increases with age, peaking in 5th-7th decade. Staphylococcal form more common in younger women. Seborrheic form increases with age. Demodex-related blepharitis more common after age 60 (100% colonization in elderly). | Burning, itching, and irritation of eyelid margins; crusting and flaking at base of lashes (collarettes in staphylococcal, greasy scales in seborrheic); eyelid erythema and swelling; madarosis (loss of lashes) in chronic cases; poliosis (whitening of lashes); trichiasis; chronic conjunctival injection; foreign body sensation; tearing; photophobia; fluctuating blurred vision from tear film instability; cylindrical dandruff at lash base (pathognomonic for Demodex). | Eyelid margins; lash follicles; conjunctiva; cornea (secondary keratitis in 25-30%) | Slit-lamp examination of lid margins showing collarettes, scales, telangiectasia, madarosis; assessment of lash follicles for Demodex (cylindrical dandruff); eyelid margin cultures if treatment-resistant; tear film assessment (TBUT, Schirmer test); evaluate for associated meibomian gland dysfunction, dry eye, and corneal involvement; Demodex count by lash epilation and microscopy (>3 mites per 4 lashes is significant). | Eyelid hygiene cornerstone: warm compresses (10 minutes twice daily), lid scrubs with dilute baby shampoo or commercial lid cleansers (Blephaclean, OCuSOFT). Topical antibiotic ointment: erythromycin 0.5% or bacitracin at bedtime for 2-4 weeks for staphylococcal form. Oral tetracycline derivatives (doxycycline 50-100mg daily for 6-12 weeks) for moderate-severe or rosacea-associated cases. Tea tree oil 50% lid scrubs or terpinen-4-ol for Demodex (twice daily for 6 weeks). Topical ivermectin 1% cream for Demodex. Intense pulsed light (IPL) therapy emerging for refractory cases. Artificial tears for concurrent dry eye. | Chronic relapsing condition requiring ongoing lid hygiene maintenance. Complete cure rare but symptoms controllable in 80-90% with consistent treatment. Exacerbations common during discontinuation of therapy. Complications include chalazia, corneal marginal infiltrates, phlyctenules, and madarosis. Long-term prognosis good for vision with appropriate management. Quality of life significantly impacted by chronic symptoms. | H01.001 |
| 3 | 2 | Blepharitis (Posterior/Meibomian) | Eyelid, Lacrimal System & Ocular Surface Disorders | Chronic inflammation of the posterior eyelid margin characterized by meibomian gland dysfunction (MGD) — obstruction and qualitative/quantitative changes in meibomian gland secretions (meibum). Meibomian glands produce the lipid layer of the tear film; dysfunction leads to evaporative dry eye. Obstructive MGD is most common form with keratinization of gland orifices and thickened meibum. Associated with rosacea (50-75% of rosacea patients have MGD), hormonal changes (androgen deficiency), contact lens wear, and aging. Chronic stasis of meibum promotes bacterial lipase activity and release of inflammatory free fatty acids. | Most common form of blepharitis; affects up to 70% of blepharitis patients. Prevalence of MGD estimated at 35-60% in Asian populations (higher prevalence) and 20-40% in Western populations. Prevalence increases significantly with age (75% in elderly). Accounts for approximately 86% of dry eye disease cases (evaporative dry eye). | Prevalence increases with age; uncommon before age 20. Most common in 5th-7th decade. Postmenopausal women at higher risk due to androgen deficiency. Contact lens wearers affected at younger ages. | Eyelid margin irregularity and thickening; capping or plugging of meibomian gland orifices with thick, opaque meibum; telangiectasia of lid margin; foamy tears (saponification of lipids); fluctuating blurred vision worse with prolonged visual tasks; burning and grittiness; foreign body sensation; rapid tear breakup time (<10 seconds); secondary corneal changes: inferior punctate epithelial erosions, marginal infiltrates, neovascularization in chronic cases; intermittent episodes of hordeola and chalazia. | Eyelid margins (meibomian glands); tear film (lipid layer deficiency); conjunctiva; cornea | Slit-lamp examination: inspect meibomian gland orifices, express meibum (assess quality — clear/cloudy/granular/toothpaste-like); non-contact meibography (infrared imaging of gland structure showing dropout/atrophy); tear film breakup time (TBUT <10 seconds); Schirmer test; interferometry (lipid layer thickness); LipiView tear interferometry; grading of MGD severity (1-4 scale); assess for associated rosacea, lid margin changes, and corneal staining. | Warm compresses (40-45°C for 10 minutes twice daily to melt obstructed meibum); lid massage after warm compresses to express glands; omega-3 fatty acid supplementation (EPA 1000mg + DHA 500mg daily — improves meibum quality); oral doxycycline 40-100mg daily for 6-12 weeks (anti-inflammatory, reduces lipase activity); azithromycin ophthalmic 1% for 3-day or monthly pulsed regimen; LipiFlow thermal pulsation system (vectored thermal pulsation, 42.5°C for 12 minutes — single treatment effective for 9-12 months); intense pulsed light (IPL) therapy; topical cyclosporine 0.05% or lifitegrast 5% for concurrent dry eye; punctal plugs if aqueous-deficient component. Probing of meibomian glands (intraductal probing) for severe obstruction. | Chronic progressive condition; meibomian gland atrophy is irreversible once advanced. Early treatment preserves gland function. LipiFlow shows sustained improvement at 12 months in 80% of patients. Warm compresses and lid hygiene provide symptom relief in 60-70% but require ongoing compliance. Dry eye symptoms are the primary long-term impact. Quality of life significantly affected. Visual prognosis good with consistent management but chronic discomfort common. | H01.009 |
| 4 | 3 | Blepharospasm | Eyelid, Lacrimal System & Ocular Surface Disorders | Involuntary bilateral forceful closure of the eyelids caused by spasms of the orbicularis oculi and periocular muscles. Benign essential blepharospasm (BEB) is an adult-onset focal dystonia of unknown cause involving basal ganglia dysfunction with loss of inhibition of the blink reflex. Secondary causes include Parkinson's disease, progressive supranuclear palsy, drug-induced (neuroleptics, levodopa), and reflex blepharospasm (from ocular surface irritation). Meige syndrome: blepharospasm combined with lower facial/oromandibular dystonia. Strongly associated with dry eye disease, photophobia, and stress. | Prevalence approximately 16-133 per million (estimated 20,000-50,000 affected in US). Female predominance (2-3:1). Mean age of onset 50-60 years. Incidence increases with age. Often underdiagnosed with average delay to diagnosis of 4-5 years. | Mean onset age 50-60 years. Rare before age 40. Slight female predominance (2-3:1). Symptoms worsen over first 5 years then typically stabilize. May be preceded by increased blinking for months to years. | Involuntary bilateral eyelid closure episodes (initially intermittent, progressing to sustained); increased blink rate and force; photophobia (90%); difficulty keeping eyes open for reading, driving, or watching television; functionally blind during severe spasms despite normal eye examination; exacerbating factors: bright lights, wind, stress, fatigue, driving, reading; alleviating factors: talking, singing, yawning, looking down; sensory tricks (geste antagoniste): touching face, wearing sunglasses; apraxia of eyelid opening (difficulty initiating voluntary opening after spasm subsides). | Orbicularis oculi and periocular muscles; basal ganglia (central nervous system dysfunction); bilateral | Clinical diagnosis based on characteristic bilateral involuntary eyelid closure episodes; absence of lower facial involvement differentiates from Meige syndrome; exclude reflex blepharospasm by treating underlying ocular surface disease; neurological examination to exclude secondary causes; brain MRI if atypical features or suspicion of secondary cause; dry eye assessment; jitter analysis and EMG of orbicularis rarely needed; response to botulinum toxin injection supports diagnosis. | Botulinum toxin type A injection (gold standard treatment): onabotulinumtoxinA (Botox) 2.5-5 units per injection site, typically 4-6 sites per eyelid (pretarsal and preseptal orbicularis); repeat every 3-4 months; effective in 85-95% of patients; incobotulinumtoxinA (Xeomin) and abobotulinumtoxinA (Dysport) are alternatives. Adjunctive measures: dark glasses/FL-41 tinted lenses for photophobia; treat concurrent dry eye disease; oral medications (benzodiazepines, trihexyphenidyl, baclofen) provide modest benefit in 30-40%. Myectomy (surgical removal of orbicularis muscle) for botulinum toxin-refractory cases (success 70-80%). Deep brain stimulation under investigation for severe refractory cases. | Chronic progressive condition that stabilizes after initial 5 years. Botulinum toxin provides sustained control in 85-95% with repeated injections. 10-15% of patients develop tolerance requiring dose adjustment. Spontaneous remission rare (<5%). Side effects of botulinum toxin: ptosis (5-15%), lagophthalmos, diplopia (temporary). Quality of life significantly impaired, especially driving and reading. Functional blindness from severe spasms despite normal visual acuity. With appropriate treatment, most patients achieve good functional control. | G24.5 |
| 5 | 4 | Chalazion | Eyelid, Lacrimal System & Ocular Surface Disorders | Chronic sterile lipogranulomatous inflammation of a meibomian gland caused by obstruction of the gland duct with retained meibum (lipid secretions) in surrounding tissue. Not an infection but a foreign body-type granulomatous reaction to extravasated lipid material. Histologically shows lipid-laden macrophages, multinucleated giant cells, and granulomatous inflammation. Associated with posterior blepharitis/MGD, rosacea, and seborrheic dermatitis. May develop from a resolved internal hordeolum. Recurrent chalazia should raise suspicion of sebaceous cell carcinoma (especially in elderly). | Very common; one of the most frequent eyelid conditions seen in clinical practice. Annual incidence estimated at 7-20 per 10,000 population. Affects all ages. More common in adults 30-50 years. Slightly more common in individuals with blepharitis, rosacea, and hyperlipidemia. | Most common in adults aged 30-50. Can occur at any age including children (peak 10-15 years in pediatric population). Recurrent chalazia more common in patients with chronic blepharitis and rosacea. Less common in elderly (reduced meibomian gland function). | Painless or mildly tender firm nodule within the eyelid (typically away from lid margin); eyelid swelling; cosmetic concern; upper lid involvement more common than lower (2:1 ratio reflecting more meibomian glands in upper lid); nodule ranges from 2-8mm; occasionally causes astigmatism if large and presses on cornea; may point and drain through conjunctival surface; chronic lesion has fibrous capsule; initial acute phase may mimic hordeolum with tenderness and erythema. | Eyelid (meibomian gland within tarsal plate); may press on cornea causing astigmatism | Clinical diagnosis based on characteristic firm eyelid nodule; slit-lamp examination to assess size, location, and relationship to lid margin; eversion of eyelid showing grey-red granulomatous tissue on tarsal conjunctiva; measure corneal astigmatism if large; recurrent or atypical lesions require biopsy to exclude sebaceous cell carcinoma (especially in elderly with unilateral recurrence, loss of lashes, or destruction of meibomian gland architecture). | Conservative management first (resolves 50% within 6 months): warm compresses (10-15 minutes 4 times daily), lid massage, and lid hygiene. Intralesional corticosteroid injection: triamcinolone acetonide 0.2-1.0mL of 5-40mg/mL into lesion through conjunctival surface (success rate 60-90% within 2 weeks; may repeat once). Incision and curettage (I&C) for persistent lesions (>4-6 weeks) or large chalazia: approach through conjunctival surface with chalazion clamp, vertical incision, curettage of granulomatous tissue (success rate >95%). Oral doxycycline 50-100mg daily for recurrent chalazia. Biopsy specimen for histopathology in recurrent cases to exclude malignancy. | Excellent prognosis. 25-50% resolve spontaneously with conservative measures. Intralesional steroid injection resolves 60-90%. Incision and curettage curative in >95%. Recurrence rate 5-10% at same site; higher with underlying MGD or rosacea. Complications rare: eyelid notching from surgery, skin depigmentation from steroid injection (especially darker skin). Sebaceous cell carcinoma must be excluded in recurrent or atypical cases. | H00.19 |
| 6 | 5 | Dacryoadenitis | Eyelid, Lacrimal System & Ocular Surface Disorders | Inflammation of the lacrimal gland (located in superolateral orbit). Acute dacryoadenitis: usually infectious — viral (most common in children: mumps, EBV, measles), bacterial (S. aureus, streptococci, N. gonorrhoeae), or rarely fungal. Chronic dacryoadenitis: autoimmune/inflammatory conditions — sarcoidosis (most common cause of bilateral chronic dacryoadenitis), IgG4-related disease, Sjogren syndrome, granulomatosis with polyangiitis (GPA), and lymphoma. Acute bacterial form rare in developed countries. Must distinguish from lacrimal gland tumors. | Acute: uncommon, exact incidence unknown. Chronic: varies with underlying cause. Sarcoidosis involves lacrimal gland in 15-28% of ocular sarcoidosis. IgG4-related disease is increasingly recognized cause. Lacrimal gland enlargement found in 25-50% of orbital inflammatory conditions. Overall relatively uncommon compared to other lacrimal pathology. | Acute viral: children and young adults (5-20 years, often associated with mumps). Acute bacterial: any age, more common in young adults. Chronic inflammatory: typically adults 30-60 years. IgG4-related disease: middle-aged to elderly males predominant. | Acute: rapid-onset unilateral (usually) pain, swelling, and erythema of superolateral eyelid; S-shaped ptosis (from lacrimal gland enlargement); tenderness over lacrimal gland; purulent discharge (bacterial); preauricular lymphadenopathy; fever and malaise. Chronic: painless bilateral (often) lacrimal gland enlargement; progressive swelling over weeks to months; dry eye symptoms (if gland function compromised); S-shaped lid contour; globe displacement inferonasally by enlarged gland. | Lacrimal gland; periorbital tissues; may involve salivary glands (systemic diseases like sarcoidosis, Sjogren, IgG4-related disease) | CT/MRI of orbits showing lacrimal gland enlargement (diffuse in inflammation, focal in tumor); distinguish from lacrimal gland tumors (tumors typically focal, may erode bone; inflammatory enlargement diffuse, molds to globe). Blood tests: CBC, ESR, CRP, ACE level (sarcoidosis), IgG4 levels, ANCA (GPA), ANA, SSA/SSB (Sjogren). Lacrimal gland biopsy if diagnosis uncertain (essential to exclude lymphoma). Chest X-ray for sarcoidosis. Viral serology in acute cases. | Acute infectious: warm compresses, oral antibiotics for bacterial (amoxicillin-clavulanate or ciprofloxacin for 10-14 days); viral — supportive care with NSAIDs. Chronic inflammatory: treat underlying disease — sarcoidosis: oral prednisone 40-60mg/day tapered over 2-4 months; IgG4-related disease: prednisone then steroid-sparing agents (rituximab, azathioprine); GPA: cyclophosphamide or rituximab; Sjogren: lubricants, pilocarpine 5mg three times daily. Lacrimal gland biopsy if lymphoma suspected. Orbital radiation for refractory inflammatory cases. | Acute viral dacryoadenitis: self-limiting with full recovery in 1-2 weeks. Acute bacterial: resolves with antibiotics, rare progression to abscess. Chronic inflammatory: prognosis depends on underlying disease. Sarcoidosis responds well to steroids but may recur. IgG4-related disease often chronic relapsing requiring long-term immunosuppression. Main concern is excluding lacrimal gland malignancy (pleomorphic adenoma or lymphoma), which requires biopsy. | H04.009 |
| 7 | 6 | Dacryocystitis | Eyelid, Lacrimal System & Ocular Surface Disorders | Infection and inflammation of the lacrimal sac, usually resulting from nasolacrimal duct obstruction (NLDO) with stasis and secondary bacterial infection. Acute dacryocystitis: S. aureus (most common), S. pneumoniae, and H. influenzae; marked erythema, pain, and swelling over medial canthal area. Chronic dacryocystitis: low-grade infection with persistent tearing and mucoid reflux. Congenital NLDO predisposes to dacryocystitis in infants. Adults: acquired NLDO from chronic inflammation, nasal pathology, trauma, or idiopathic fibrosis. Complication: preseptal and orbital cellulitis, lacrimal sac abscess, dacryocystocele. | Acute dacryocystitis: incidence approximately 2-3 per 100,000 per year. Chronic dacryocystitis parallels NLDO prevalence (3-5% of adults). More common in women (3:1) possibly due to narrower nasolacrimal duct anatomy. Congenital NLDO affects 5-20% of newborns but most resolve spontaneously. | Acute: most common in 5th-7th decade. Chronic: any age with NLDO. Congenital: presents in first weeks to months of life. Female predominance in adults (3:1). More common in winter months (concurrent upper respiratory infections). | Acute: painful red swelling over medial canthal region (below medial canthal tendon — distinguishing from preseptal cellulitis); purulent discharge on pressure over lacrimal sac; epiphora (tearing); conjunctival injection; fever in severe cases; abscess formation with fluctuance; extension to preseptal or orbital cellulitis possible. Chronic: persistent tearing; mucoid or mucopurulent reflux on pressure over lacrimal sac; recurrent conjunctivitis; painless distension of lacrimal sac (mucocele/dacryocystocele). | Lacrimal sac; nasolacrimal duct; may extend to periorbital tissues | Clinical diagnosis based on characteristic location (below medial canthal tendon), tenderness, and purulent reflux from puncta on pressure. Regurgitation test (pressure over lacrimal sac produces reflux from puncta). CT scan of orbits and sinuses if orbital cellulitis suspected or atypical presentation. Culture of purulent material expressed from puncta. Nasolacrimal duct probing contraindicated in acute infection. Dacryocystography or dacryoscintigraphy for chronic cases to document obstruction site. | Acute: warm compresses; topical antibiotic drops (moxifloxacin 0.5% 4 times daily); oral antibiotics (amoxicillin-clavulanate 875/125mg twice daily for 10-14 days or cephalexin 500mg four times daily); incision and drainage if pointing abscess; IV antibiotics if preseptal cellulitis (ceftriaxone 1g IV daily). Definitive surgery after acute infection resolved (4-6 weeks): dacryocystorhinostomy (DCR) — external or endoscopic, creates new pathway from lacrimal sac to nasal cavity (success rate 90-95% external DCR, 85-90% endoscopic DCR). Congenital: nasolacrimal duct probing (success 80-95% if performed by age 12 months); balloon dacryoplasty or intubation for failed probing. | Excellent prognosis with appropriate treatment. DCR surgery achieves long-term resolution of tearing and infection in 90-95% (external) and 85-90% (endoscopic). Acute dacryocystitis resolves with antibiotics but recurs without DCR in 30-50%. Congenital NLDO spontaneously resolves by age 12 months in 90% without intervention. Complications of untreated dacryocystitis: orbital cellulitis, dacryocystocele rupture, fistula formation. Early surgical intervention recommended for recurrent cases. | H04.309 |
| 8 | 7 | Dermatochalasis | Eyelid, Lacrimal System & Ocular Surface Disorders | Redundancy and laxity of eyelid skin resulting from loss of elastic tissue, thinning of connective tissue, and attenuation of the orbital septum allowing orbital fat prolapse. Predominantly an age-related involutional change. Contributing factors include chronic sun exposure, gravity, genetic predisposition, smoking, and atopic dermatitis. Bilateral and symmetric in most cases. Distinguished from blepharoptosis (lid margin position is normal in dermatochalasis). Severe upper lid dermatochalasis can cause functional visual field loss (pseudoptosis). | Extremely common age-related change; present in varying degrees in majority of population over 50 years. One of the most common reasons for oculoplastic referral. Affects both sexes. More pronounced in fair-skinned individuals with sun damage. Prevalence increases dramatically with each decade after 40. | Begins in 4th decade; progressively worsens with age. Present in nearly all individuals >70 years to some degree. Upper lid more functionally significant than lower lid. Occasionally present in young adults with atopic dermatitis or familial predisposition. | Excess upper eyelid skin overhanging lid margin (lateral more than medial); hooding of skin creating fold; superior visual field restriction in severe cases; heaviness and fatigue of eyelids by end of day; difficulty applying eye makeup; lateral visual field obstruction; compensatory brow elevation (frontalis overaction) and headaches; cosmetic concern; lower lid festoons (mounds of redundant skin and orbicularis); orbital fat prolapse creating 'bags' under eyes; pseudoptosis (skin weight drags lid margin down). | Upper and lower eyelid skin and soft tissues; orbital septum (attenuation allowing fat prolapse) | Clinical examination documenting excess upper lid skin; measurement of MRD1 and levator function (to differentiate from true ptosis — levator function normal in dermatochalasis); visual field testing with and without eyelid taping (must demonstrate ≥12 degrees or 30% superior field improvement for insurance coverage of functional blepharoplasty); external photography in primary gaze; assess for concurrent ptosis (commonly coexists); evaluate lower lid laxity and festoons; rule out floppy eyelid syndrome, thyroid eye disease, and orbital masses. | Upper lid blepharoplasty (most common cosmetic and functional eyelid surgery): excision of redundant skin and orbicularis muscle, with or without orbital fat removal; performed under local anesthesia as outpatient; incision in lid crease (hidden in natural fold). Lower lid blepharoplasty: transconjunctival approach (fat removal only, no visible scar) or transcutaneous approach (skin-muscle flap). Chemical brow peeling and laser resurfacing for mild cases. CO2 laser may be used for skin excision. Conservative measures: cold compresses, elevation for morning edema. Insurance covers functional blepharoplasty when documented visual field impairment meets criteria. | Excellent surgical outcomes: >95% patient satisfaction after functional blepharoplasty. Visual field improvement of 50-100% in superior field. Complication rate low (<2%): hematoma, asymmetry, under/overcorrection, lagophthalmos (rare). Recurrence possible over decades as aging continues. Lower lid blepharoplasty outcomes similarly excellent. Combined blepharoplasty-ptosis repair often needed. Quality of life improvement significant both functionally and cosmetically. | H02.839 |
| 9 | 8 | Dry Eye Disease (Keratoconjunctivitis Sicca) | Eyelid, Lacrimal System & Ocular Surface Disorders | Multifactorial disease of the ocular surface characterized by loss of tear film homeostasis with tear film instability, hyperosmolarity, ocular surface inflammation, and neurosensory abnormalities. Two major subtypes: aqueous-deficient dry eye (Sjogren and non-Sjogren, 15-20% of cases) and evaporative dry eye (meibomian gland dysfunction, 50-65% of cases, often with mixed mechanism). Risk factors: aging, female sex, postmenopausal estrogen deficiency, autoimmune disease, medications (antihistamines, antidepressants, beta-blockers), screen use (reduced blink rate), contact lens wear, refractive surgery (LASIK), and low humidity environments. | One of the most common ophthalmologic conditions; prevalence 5-50% depending on criteria used (symptoms vs signs). DEWS II estimates 5-15% prevalence in developed countries. Affects approximately 16 million diagnosed adults in the US. Prevalence increases significantly with age (15-33% in adults >65). Female predominance (2:1). Higher prevalence in Asian populations. | Prevalence increases with age; uncommon before age 30. Significant increase after age 50, particularly in postmenopausal women. Screen-related dry eye increasingly common in younger adults (20-40). Sjogren syndrome typically presents 40-60 years. | Burning, stinging, and grittiness (most common symptoms); foreign body sensation; fluctuating blurred vision (improves with blinking); tearing (paradoxical reflex tearing); photophobia; eye fatigue; contact lens intolerance; red eyes; stringy mucous discharge; symptoms worse with prolonged reading, screen use, driving, and in air-conditioned or heated environments; corneal and conjunctival staining (punctate epithelial erosions); filamentary keratitis in severe cases. | Ocular surface (cornea, conjunctiva); lacrimal gland; meibomian glands; tear film; eyelids; systemic associations (Sjogren syndrome, rheumatoid arthritis, SLE) | OSDI questionnaire (Ocular Surface Disease Index) or DEQ-5 for symptoms; tear breakup time (TBUT <10s abnormal); Schirmer test (I — without anesthesia: <10mm in 5 min; II — with anesthesia: <5mm suggests aqueous deficiency); corneal and conjunctival staining with fluorescein, lissamine green, or rose bengal; tear osmolarity (>308 mOsm/L or >8 mOsm/L difference between eyes); MMP-9 testing (InflammaDry); meibography for gland assessment; LipiView interferometry; Sjogren testing (SSA/SSB antibodies, salivary gland biopsy) if suspected. | Stepwise approach based on severity. Mild: preservative-free artificial tears 4-8 times daily; lid hygiene; omega-3 supplementation (2-3g daily); environmental modifications. Moderate: topical anti-inflammatory therapy — cyclosporine 0.05% (Restasis) or 0.09% (Cequa) twice daily; lifitegrast 5% (Xiidra) twice daily; short-course topical steroids (loteprednol 0.25% for 2-4 weeks); punctal plugs (silicone or collagen) for aqueous deficiency; warm compresses and lid massage for MGD. Severe: autologous serum tears 20-50% (4-8 times daily); therapeutic contact lenses (scleral lenses, PROSE); LipiFlow thermal pulsation; IPL therapy; oral secretagogues (pilocarpine 5mg TID, cevimeline 30mg TID) for Sjogren. Refractory: tarsorrhaphy; amniotic membrane; salivary gland transplantation. | Chronic condition requiring ongoing management. Mild-moderate dry eye: symptoms controllable in 70-80% with consistent treatment. Anti-inflammatory therapy (cyclosporine, lifitegrast) takes 3-6 months for full effect but provides sustained improvement in 50-70%. Punctal plugs effective in 60-70% of aqueous-deficient cases. Meibomian gland loss is irreversible once advanced (early treatment important). Quality of life significantly impacted. Complications of severe untreated dry eye include corneal ulceration, scarring, and rarely perforation. Overall visual prognosis good with appropriate long-term management. | H04.129 |
| 10 | 9 | Ectropion | Eyelid, Lacrimal System & Ocular Surface Disorders | Outward turning of the eyelid margin away from the globe, predominantly affecting the lower lid. Types: involutional (most common — horizontal lid laxity, canthal tendon dehiscence from aging); cicatricial (skin shortening from burns, trauma, chronic dermatitis, skin cancer excision); paralytic (facial nerve (CN VII) palsy — loss of orbicularis tone); mechanical (eyelid tumors, edema weighing lid down); congenital (rare, associated with Down syndrome). Exposes palpebral conjunctiva leading to keratinization, punctal eversion, and impaired tear drainage. | Involutional ectropion: prevalence 2-5% in population >60 years, increasing with age. Paralytic: incidence parallels facial nerve palsy (20-25 per 100,000 per year). Common eyelid problem in elderly requiring oculoplastic referral. More common in lower eyelid. | Involutional: >60 years. Cicatricial: any age depending on cause. Paralytic: any age (Bell's palsy peak 15-45 years; stroke-related in elderly). Congenital: present at birth. | Lower lid margin turned outward away from globe; chronic tearing (epiphora) from punctal malposition and poor tear drainage; conjunctival exposure and keratinization (thickened, erythematous conjunctiva); chronic conjunctivitis; eczematous changes of lower lid skin from chronic tearing (vicious cycle — wiping worsens laxity); incomplete lid closure (lagophthalmos in paralytic); exposure keratopathy in severe cases; mucous discharge; cosmetic disfigurement. | Eyelid (lower lid predominantly); conjunctiva (exposure keratinization); cornea (exposure keratopathy in severe cases); lacrimal drainage system (functional obstruction) | Clinical examination demonstrating outward-turning lid margin; snap-back test and lid distraction test for laxity assessment; evaluate punctal position (everted punctum causes epiphora); assess medial and lateral canthal tendon integrity; facial nerve function testing for paralytic type; evaluate skin shortage (cicatricial type — lid fails to close even with manual push); assess corneal exposure and staining; photograph for documentation. | Lubricating drops and ointment for corneal protection. Definitive surgical correction: involutional — lateral tarsal strip procedure (horizontal lid tightening, most versatile, success 90-95%); medial ectropion repair with medial spindle procedure or lazy-T procedure; cicatricial — skin graft (full-thickness from upper lid or postauricular) or skin flap to replace contracted skin; paralytic — temporary tarsorrhaphy or gold/platinum weight implant in upper lid for paralytic lagophthalmos; lower lid horizontal tightening; medial canthoplasty for punctal ectropion. Botulinum toxin to reduce aberrant facial nerve regeneration symptoms. | Excellent surgical outcomes: 90-95% success for involutional ectropion with appropriate procedure. Cicatricial ectropion outcomes depend on severity of scarring and adequacy of skin graft. Paralytic ectropion prognosis parallels facial nerve recovery (Bell's palsy: 85% spontaneous recovery within 3-6 months). Without treatment, chronic conjunctival exposure leads to keratinization, and corneal exposure can cause ulceration. Long-term functional and cosmetic results generally very good. | H02.109 |
| 11 | 10 | Entropion | Eyelid, Lacrimal System & Ocular Surface Disorders | Inward turning of the eyelid margin causing lashes to contact the corneal and conjunctival surface. Types: involutional (most common, age-related laxity of lower lid retractors, orbicularis overriding, and horizontal lid laxity); cicatricial (scarring of conjunctival surface from trachoma, chemical burns, Stevens-Johnson syndrome, ocular cicatricial pemphigoid); spastic (reflex orbicularis spasm from ocular irritation); congenital (rare). Lower lid involvement much more common than upper lid (except cicatricial type). Chronic corneal contact with lashes causes epithelial breakdown, scarring, and risk of microbial keratitis. | Involutional entropion: prevalence 2-4% in population >60 years. Common cause of eyelid surgery in elderly. Cicatricial entropion: depends on underlying cause (trachoma-endemic regions have high prevalence). Overall incidence increases with age. More common in lower lid (95% for involutional). | Involutional: >60 years, increasing with age. Cicatricial: any age depending on cause (trachoma typically 30-50 years). Spastic: any age during acute ocular irritation. Congenital: present at birth. | Eyelid margin turned inward with lashes touching ocular surface; foreign body sensation; tearing (epiphora); ocular irritation and redness; corneal abrasion from lash contact; recurrent corneal erosions; corneal scarring, thinning, and neovascularization if chronic; secondary microbial keratitis risk; photophobia; mucous discharge. Spastic entropion may be intermittent. Cicatricial entropion affects upper lid more frequently with trichiasis. | Eyelid margin; conjunctiva; cornea (secondary damage from trichiasis) | Clinical examination showing inward-turned lid margin with lashes contacting globe; snap-back test (lid pulled away and released — slow return indicates laxity); lid distraction test (>6mm indicates laxity); assessment of lower lid retractor disinsertion (reduced lower lid excursion on downgaze); evaluate conjunctival scarring with slit-lamp (cicatricial type); corneal staining with fluorescein to document surface damage; differentiate from epiblepharon and trichiasis without entropion. | Temporary measures: taping lid into eversion; botulinum toxin A injection (2.5-5 units into preseptal orbicularis, effective 3-4 months) for acute or spastic entropion. Definitive surgical repair: involutional — transverse lid split with everting sutures (Quickert sutures, temporary); horizontal lid shortening (lateral tarsal strip) combined with lower lid retractor reinsertion (Jones procedure, success 85-95%); Wies procedure (transverse blepharotomy with marginal rotation). Cicatricial: tarsal fracture with marginal rotation, posterior lamellar graft (mucous membrane or hard palate) for severe scarring. Protect cornea with lubricants until surgery. | Excellent surgical outcomes for involutional entropion: 85-95% success with combined horizontal tightening and retractor repair. Recurrence rate 5-10% at 5 years. Cicatricial entropion has higher recurrence rate (15-25%) due to ongoing scarring process. Without treatment, chronic corneal damage can lead to ulceration, scarring, and significant vision loss. Prompt surgical correction prevents corneal complications. | H02.009 |
| 12 | 11 | Floppy Eyelid Syndrome | Eyelid, Lacrimal System & Ocular Surface Disorders | Characterized by markedly lax and easily everted upper eyelids that spontaneously evert during sleep causing corneal and conjunctival exposure and papillary conjunctivitis. Strong association with obstructive sleep apnea (OSA, present in 90-100% of FES patients). Also associated with obesity (BMI >30 in 80-90%), keratoconus, Down syndrome, and elevated leptin levels. Mechanism: chronic mechanical trauma from eyelid eversion against pillow during sleep combined with elastic fiber degeneration (decreased elastin in tarsal plate). Predominantly affects overweight middle-aged men. | Prevalence estimated at 3-4% of general ophthalmology patients; likely underdiagnosed. Present in 2-32% of patients with OSA depending on diagnostic criteria. Male predominance (5-20:1). Prevalence increases with severity of OSA and BMI. | Most common in overweight males aged 40-60 years. Mean age at diagnosis approximately 50 years. Rare in normal-weight individuals. Strong male predominance. | Chronic unilateral or bilateral eye irritation worse on waking (especially on side patient sleeps on); conjunctival injection and papillary conjunctivitis on upper palpebral conjunctiva; mucous discharge; foreign body sensation; upper eyelid easily everts with minimal upward traction (diagnostic sign); rubbery, floppy upper eyelid tarsus; corneal punctate epithelial erosions; corneal pannus and neovascularization in chronic cases; lash ptosis (lashes pointing downward); symptoms often worse on the side of habitual sleep position. | Upper eyelids (tarsal plate — loss of elasticity); conjunctiva (papillary conjunctivitis); cornea (exposure); systemically associated with OSA | Clinical examination: upper lid easily everts with minimal upward traction on lid (eversion should not normally occur with this maneuver); papillary conjunctivitis on everted upper palpebral conjunctiva; lash ptosis; assess horizontal lid laxity (distraction >15mm, no snap-back); corneal staining; ask about sleep apnea symptoms (snoring, daytime somnolence); refer for polysomnography (sleep study) — >90% will have OSA; BMI measurement; evaluate for keratoconus (associated in 15-30%). | Treat underlying OSA (CPAP therapy — often improves ocular symptoms significantly). Eye shield or sleep goggles to prevent lid eversion during sleep (tape eyelids or foam shield). Sleep position modification (avoid sleeping on affected side). Lubricating drops and ointment. Topical anti-inflammatory (fluorometholone 0.1% for papillary conjunctivitis). Definitive: horizontal lid shortening (lateral tarsal strip or full-thickness pentagon excision) to reduce lid laxity (success 80-90%). Weight loss (reduces both OSA and FES severity). | Good prognosis with appropriate management. CPAP therapy for OSA often provides significant ocular symptom improvement. Lid tightening surgery effective in 80-90% for ocular symptoms. Without treatment, chronic corneal exposure can lead to scarring and decreased vision. Screening all FES patients for OSA is critical given the 90-100% association (untreated OSA carries significant cardiovascular morbidity). Weight loss benefits both conditions. | H02.89 |
| 13 | 12 | Hordeolum (Stye) | Eyelid, Lacrimal System & Ocular Surface Disorders | Acute localized bacterial infection of eyelid glands. External hordeolum: infection of glands of Zeis (sebaceous) or Moll (apocrine sweat glands) at lash follicle base. Internal hordeolum: acute infection of meibomian gland (larger, deeper, more painful). Most commonly caused by Staphylococcus aureus (90-95% of cases). Risk factors include blepharitis, poor lid hygiene, stress, hormonal changes, and immunosuppression. May progress to preseptal cellulitis if untreated. Internal hordeolum may evolve into chalazion if chronic. | Extremely common; lifetime prevalence estimated at 5-10%. Annual incidence not well documented but one of the most frequent acute eyelid complaints. Affects all ages with no sex predominance. More common in patients with blepharitis and rosacea. | Can occur at any age; peak incidence in 3rd-5th decade. Common in children and adolescents. Recurrence more common in patients with chronic blepharitis. | Acute painful swollen red lump on eyelid; tenderness; localized erythema and edema; external hordeolum: small yellow pustule at lash base pointing anteriorly; internal hordeolum: larger, deeper swelling, may point through conjunctival surface; tearing; foreign body sensation; photophobia (if corneal irritation); may develop preseptal cellulitis if spreading infection; spontaneous drainage of pus common after 5-7 days. | Eyelid (glands of Zeis/Moll for external; meibomian glands for internal); may involve periorbital tissues if cellulitis develops | Clinical diagnosis based on characteristic acute eyelid swelling with pointing abscess; slit-lamp examination to localize and differentiate external vs internal hordeolum; differentiate from chalazion (acute vs chronic, tender vs non-tender); assess for preseptal cellulitis signs (diffuse lid swelling, fever, leukocytosis); culture of expressed material if recurrent or treatment-resistant; evaluate for underlying blepharitis. | Warm compresses 10-15 minutes 4 times daily (promotes drainage, resolves 90% within 1-2 weeks). Avoid squeezing or manual expression. Topical antibiotic ointment (erythromycin 0.5% or bacitracin 3 times daily for 7 days) may prevent secondary infection. Incision and drainage if not resolving after 2-4 weeks or if large pointing abscess. Oral antibiotics (amoxicillin-clavulanate 875/125mg twice daily for 7-10 days or cephalexin 500mg four times daily) if associated preseptal cellulitis. Treat underlying blepharitis to prevent recurrence. | Excellent prognosis; 90% resolve spontaneously within 1-3 weeks with warm compresses alone. I&D curative for persistent lesions. May evolve into chronic chalazion in 15-25% (requiring separate management). Recurrence common in patients with untreated blepharitis (30-40%). Preseptal cellulitis rare but requires systemic antibiotics. Vision-threatening complications extremely rare. | H00.019 |
| 14 | 13 | Lagophthalmos | Eyelid, Lacrimal System & Ocular Surface Disorders | Incomplete closure of the eyelids leaving a portion of the cornea or conjunctiva exposed. Causes: paralytic (facial nerve CN VII palsy — Bell's palsy most common, surgery, stroke, tumor); mechanical (proptosis from thyroid eye disease, orbital tumors); cicatricial (burns, post-surgical skin shortage, scleroderma); nocturnal (physiological incomplete closure during sleep in up to 20% of normal population). Corneal exposure leads to desiccation, epithelial breakdown, ulceration, and potentially perforation. Bell's phenomenon (upward rotation of globe during attempted closure) provides some natural protection. | Paralytic lagophthalmos parallels facial nerve palsy incidence (20-25 per 100,000/year). Nocturnal lagophthalmos may affect up to 20% of the general population (usually benign). Thyroid-associated lagophthalmos in 30-50% of Graves' ophthalmopathy. Overall significant clinical lagophthalmos requiring treatment is relatively common in neuro-ophthalmology and oculoplastic practice. | Any age depending on cause. Bell's palsy peak 15-45 years. Thyroid-related: 30-60 years. Post-surgical: any age. Nocturnal: more common in elderly. Neonatal facial nerve palsy from birth trauma. | Inability to fully close eyelids; exposure keratopathy (punctate epithelial erosions to frank ulceration); foreign body sensation; tearing (paradoxical — reflex tearing from exposure); eye redness; photophobia; morning symptoms (worse upon waking due to nocturnal exposure); corneal haze, scarring, and neovascularization in chronic cases; corneal perforation in severe untreated cases; lower eyelid retraction and ectropion in paralytic causes; Bell's phenomenon assessment important (poor Bell's increases corneal risk). | Eyelids (orbicularis oculi paralysis or mechanical restriction); cornea (exposure); conjunctiva | Measurement of lagophthalmos in mm (distance between upper and lower lid margins during gentle and forced closure); assessment of Bell's phenomenon; corneal examination for exposure keratopathy (fluorescein staining); facial nerve function assessment (House-Brackmann grading); evaluate for thyroid eye disease (proptosis, lid retraction); assess nocturnal closure; Schirmer test; identify underlying cause; photography for documentation. | Lubrication: preservative-free artificial tears hourly during day, lubricating ointment at bedtime, moisture chamber goggles at night. Taping eyelids closed at night. Temporary tarsorrhaphy (suturing eyelids partially closed) for acute severe exposure. Gold or platinum weight implantation in upper eyelid (0.8-1.6g) for paralytic lagophthalmos (most common permanent solution, success 85-90%). Lower lid horizontal tightening if concurrent ectropion. Spring-loaded lid implants (rarely used). Treat underlying cause: Bell's palsy — oral prednisone 60-80mg daily for 1 week with taper, valacyclovir 1g three times daily for 7 days; thyroid eye disease — orbital decompression, lid lengthening. Botulinum toxin to contralateral retracted lid for symmetry. | Bell's palsy: 85% recover facial nerve function within 3-6 months (House-Brackmann I-II). Persistent paralytic lagophthalmos from other causes has good outcomes with gold weight implantation (90% improvement in corneal exposure). Without treatment, corneal ulceration and perforation can occur leading to permanent vision loss. Nocturnal lagophthalmos generally benign with lubricants. Long-term prognosis depends on underlying cause and corneal protection achieved. | H02.209 |
| 15 | 14 | Nasolacrimal Duct Obstruction (Congenital) | Eyelid, Lacrimal System & Ocular Surface Disorders | Failure of canalization of the nasolacrimal duct at the valve of Hasner (distal membrane at inferior meatus) resulting in impaired tear drainage. Most common cause of epiphora in infants. An imperforate membrane at the distal end of the nasolacrimal duct persists after birth. Other causes of congenital NLDO include bony abnormalities and dacryocystocele (mucocele). Stasis of tears in the lacrimal sac predisposes to secondary bacterial infection (dacryocystitis). Bilateral in 30-40% of cases. | Most common congenital anomaly of the lacrimal system. Present in 5-20% of newborns (some estimates up to 30%). Majority resolve spontaneously by age 12 months. Clinically significant NLDO requiring intervention in approximately 2-6% of infants. No sex or racial predominance. | Presents within first weeks to months of life, typically noticed by 2-4 weeks of age when tear production begins. Symptoms usually appear within first 3 months. Spontaneous resolution by 6 months in 70%, by 12 months in 90%. Persistent cases beyond 12-13 months may require intervention. | Unilateral or bilateral persistent tearing (epiphora) from first weeks of life; mucoid or mucopurulent discharge (not frankly purulent unless secondary infection); crusting of lashes upon waking; matting of eyelids; reflux of mucopurulent material when pressure applied over lacrimal sac; increased tearing in cold or windy conditions; erythema of lower lid and cheek from chronic wetness; recurrent episodes of conjunctivitis; acute dacryocystitis (red painful swelling over lacrimal sac) in 2-3%; dacryocystocele (blue-tinged swelling at medial canthus present at birth) requires urgent management. | Nasolacrimal duct (valve of Hasner); lacrimal sac; may affect nasal mucosa (dacryocystocele can cause nasal obstruction in neonates) | Clinical diagnosis: persistent tearing and discharge from birth; fluorescein dye disappearance test (instill fluorescein, assess clearance after 5 minutes — retained dye indicates obstruction); digital pressure over lacrimal sac producing mucoid reflux from puncta (diagnostic); differentiate from infantile glaucoma (check corneal diameter, IOP, clarity) and conjunctivitis; dacryocystocele visible as firm blue mass at medial canthus at birth; CT scan only if dacryocystocele with respiratory compromise or atypical presentation. | Conservative management first (effective in 90% by age 12 months): Crigler massage (digital pressure over lacrimal sac in downward strokes, 5-10 strokes 2-3 times daily) to hydrostically open distal membrane; topical antibiotics (erythromycin 0.5% ointment or moxifloxacin drops) for purulent discharge episodes; warm compresses. If persistent beyond 12-13 months: nasolacrimal duct probing under general anesthesia (success rate 80-95% for first probing); balloon dacryoplasty (catheter dilation, success 85-90%); nasolacrimal intubation with silicone tubes for failed probing (success 85-95%, tubes removed at 3-6 months). Dacryocystocele: urgent probing if nasal extension or respiratory compromise; topical and systemic antibiotics if infected. | Excellent prognosis. 90% resolve spontaneously by age 12 months with conservative management alone. Probing success rate 80-95% when performed at 12-15 months. Success rate decreases with age (60-70% if performed after 24 months). Balloon dacryoplasty and intubation effective for failed probing. Dacryocystorhinostomy (DCR) very rarely needed in children. Long-term tear drainage function normal in 95-98% after successful treatment. | Q10.5 |
| 16 | 15 | Ptosis (Acquired) | Eyelid, Lacrimal System & Ocular Surface Disorders | Drooping of the upper eyelid below normal position (upper lid margin normally 1-2mm below superior limbus). Acquired forms: aponeurotic (most common, 80% — dehiscence or disinsertion of levator aponeurosis from aging, surgery, or chronic inflammation); myogenic (myasthenia gravis, myotonic dystrophy, chronic progressive external ophthalmoplegia); neurogenic (third nerve palsy, Horner syndrome); mechanical (eyelid mass, scarring, edema); traumatic. Aponeurotic ptosis results from stretching or dehiscence of levator aponeurosis at its tarsal insertion, often accelerated by contact lens wear, eyelid rubbing, and aging. | Aponeurotic ptosis is extremely common in elderly; present in 10-15% of population >70 years. One of the most common eyelid conditions referred for oculoplastic surgery. Myasthenia gravis-associated ptosis: 15 per 100,000. Third nerve palsy incidence: 3-5 per 100,000 per year. Horner syndrome incidence: approximately 1 per 6,000. | Aponeurotic: typically >50 years, increasing with age; involutional. Myasthenic ptosis: bimodal (young women 20-40, older men 60-80). Neurogenic: any age depending on cause. Congenital ptosis (dysgenesis of levator muscle, separate entity) present at birth. | Upper eyelid drooping partially or completely covering pupil; superior visual field restriction; compensatory chin-up head posture and brow elevation (frontalis overaction); fatigue of eyelid elevation by end of day (suggestive of myasthenia); variable vs constant ptosis; asymmetric vs symmetric involvement; associated Horner syndrome triad (ptosis, miosis, anhidrosis) in sympathetic pathway lesions; pupil-involving third nerve palsy (urgent — rule out posterior communicating artery aneurysm); Cogan lid twitch sign in myasthenia. | Upper eyelid (levator palpebrae superioris muscle and aponeurosis); may indicate systemic disease (myasthenia, brain tumor, carotid dissection) | Margin reflex distance 1 (MRD1, normal ≥4mm); levator function (excursion, normal ≥12mm); palpebral fissure height; upper lid crease position (elevated in aponeurotic, absent in myogenic); ice test and acetylcholine receptor antibodies for myasthenia; pharmacological testing (phenylephrine 2.5% for Horner syndrome, may improve 1-2mm by stimulating Muller's muscle); pupil assessment for third nerve palsy or Horner syndrome; CT/MRI if neurogenic cause suspected; visual field testing documenting superior field loss for insurance authorization. | Aponeurotic ptosis: external levator advancement or reinsertion (gold standard, success rate 85-95%); internal approach (Muller's muscle-conjunctival resection, MMCR) for mild ptosis with positive phenylephrine test (success 90%); frontalis sling suspension with silicone rod or fascia lata for severe ptosis with poor levator function (<4mm). Myasthenic ptosis: pyridostigmine 60mg three times daily; immunosuppression (prednisone, azathioprine). Third nerve palsy: treat underlying cause (aneurysm — urgent neurosurgical intervention). Horner syndrome: evaluate for carotid dissection, Pancoast tumor. | Aponeurotic ptosis: excellent surgical outcomes with 85-95% achieving satisfactory lid height. Recurrence rate 5-10% over 5 years. Myasthenic ptosis: variable, depends on disease control. Third nerve palsy: recovery depends on etiology (microvascular 80-90% spontaneous recovery in 3 months; compressive requires intervention). Horner syndrome prognosis depends on underlying cause. Overall functional and cosmetic outcomes good with appropriate treatment. | H02.409 |
| 17 | 16 | Trichiasis | Eyelid, Lacrimal System & Ocular Surface Disorders | Misdirection of eyelashes toward the ocular surface from a normally positioned eyelid margin, causing corneal and conjunctival abrasion. Distinguished from entropion (where the entire lid margin is inverted) and distichiasis (extra row of lashes from meibomian gland orifices). Causes: chronic blepharitis (most common in developed countries), trachoma (most common worldwide), chemical burns, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, herpes zoster ophthalmicus, surgical or traumatic lid margin scarring. Chronic corneal abrasion leads to epithelial defects, scarring, neovascularization, and risk of infectious keratitis. | Trachomatous trichiasis affects approximately 1.9 million people worldwide (WHO). In developed countries, prevalence related to blepharitis and other chronic lid inflammation — estimated 2-3% of elderly population. Common cause of ocular discomfort and corneal damage. Higher prevalence in trachoma-endemic regions (Africa, Asia). | Any age depending on cause. Trachomatous trichiasis: typically adults 30-60 years (years after active trachoma). Blepharitis-related: elderly patients. Post-surgical/traumatic: any age. Congenital distichiasis: present from birth. | Foreign body sensation; ocular irritation and pain; tearing; photophobia; conjunctival injection; corneal epithelial defects and punctate staining at sites of lash contact; corneal scarring and pannus (chronic); corneal ulceration and secondary infection risk; decreased visual acuity if central corneal scarring; one or multiple misdirected lashes contacting globe. | Eyelashes (misdirected); cornea (abrasion, scarring); conjunctiva; eyelid margin | Slit-lamp examination identifying misdirected lashes touching corneal or conjunctival surface; fluorescein staining to document corneal epithelial damage; assess eyelid margin position (normal in trichiasis vs inverted in entropion); evaluate for underlying cause (trachomatous scarring, blepharitis, cicatricial changes); count and map misdirected lashes; assess corneal scarring and neovascularization; differentiate from distichiasis (extra row of lashes emerging from meibomian gland orifices). | Epilation (simple removal of offending lashes) — temporary relief, regrowth in 4-6 weeks, useful as initial/temporizing measure. Electrolysis (electrosurgical destruction of lash follicle, success 50-70% per session). Cryotherapy (double freeze-thaw technique to lid margin, destroys 80-90% of treated follicles; complications: skin depigmentation, lid notching). Argon laser photoablation of individual lash follicles (success 50-70%). Radiofrequency ablation. Surgical: anterior lamellar repositioning for multiple lashes with trachomatous scarring; posterior lamellar tarsal rotation if concurrent entropion. Lubricating drops and bandage contact lens for corneal protection during treatment. | Depends on underlying cause and number of affected lashes. Epilation provides temporary relief but does not address root cause. Definitive follicle destruction achieves permanent resolution in 70-90% of individual lashes. Trachomatous trichiasis: post-surgical trichiasis recurrence 10-40% at 1 year (higher rates in endemic regions). Chronic corneal damage may cause permanent visual impairment if untreated. Early treatment prevents corneal scarring. Overall prognosis good with definitive treatment and management of underlying condition. | H02.059 |
| 18 | 17 | Xanthelasma Palpebrarum | Eyelid, Lacrimal System & Ocular Surface Disorders | Yellowish lipid-laden plaques deposited in the skin of the eyelids, representing the most common cutaneous xanthoma. Composed of lipid-laden foam cells (macrophages) in the dermis. Associated with hyperlipidemia in approximately 50% of patients (elevated LDL, reduced HDL, hypertriglyceridemia). Also occurs with normal lipid levels in 50%. Risk marker for cardiovascular disease even in normolipidemic patients (increased risk of atherosclerosis, myocardial infarction, and ischemic heart disease). Bilateral and often symmetric. More common near medial canthus of upper eyelid. | Common finding; prevalence approximately 1-4% of general population. More common in women (2:1). Prevalence increases with age. Present in 1.5% of adults in large population-based studies. Significantly higher in patients with familial hypercholesterolemia (up to 25%). | Most common in 4th-6th decade (ages 30-50). Rare before age 30. More common in postmenopausal women. Can develop in younger patients with familial hypercholesterolemia. | Soft, yellowish, flat or slightly elevated plaques on eyelid skin, most commonly on upper medial eyelid; bilateral and symmetric in majority; non-tender; slowly enlarge over months to years; cosmetically disfiguring; no visual impairment unless very large; may occur on all four eyelids; sharply demarcated borders; associated with arcus cornealis (lipid ring in corneal periphery) in 50% of patients with hyperlipidemia. | Eyelid skin (dermis); systemic association with cardiovascular disease and dyslipidemia | Clinical diagnosis based on characteristic appearance (yellow eyelid plaques); fasting lipid panel essential (total cholesterol, LDL, HDL, triglycerides) — abnormal in 50%; consider lipoprotein(a) and apolipoprotein B; cardiovascular risk assessment; thyroid function (hypothyroidism causes secondary dyslipidemia); liver function tests; fasting glucose (diabetes association). Biopsy rarely needed but shows foam cells (lipid-laden macrophages) in dermis. Screen for familial hypercholesterolemia if young onset or severe hyperlipidemia. | Treat underlying dyslipidemia (statins, lifestyle modification) but medical treatment alone rarely resolves xanthelasma. Surgical excision (most common treatment, success but 40-60% recurrence at 5 years). Trichloroacetic acid (TCA) 70% chemical cauterization (success 90%, recurrence 30%). CO2 laser ablation (effective, minimal scarring, recurrence 10-20%). Argon laser therapy. Radiofrequency ablation. Cryotherapy. No treatment is uniformly effective at preventing recurrence. | Benign condition with no vision-threatening complications. Main concerns are cosmetic and systemic cardiovascular risk. Recurrence after treatment is common (40-60% after surgical excision, lower with laser or TCA). Cardiovascular risk: patients with xanthelasma have 40-50% increased risk of myocardial infarction and ischemic heart disease (Copenhagen Heart Study). Lipid management is important regardless of treatment of skin lesion. Prognosis for life depends on cardiovascular risk factor management. | H02.60 |
| 19 | ▸ Conjunctival & Scleral Disorders | |||||||||||
| 20 | 18 | Allergic Conjunctivitis | Conjunctival & Scleral Disorders | IgE-mediated type I hypersensitivity reaction of the conjunctiva to environmental allergens. Seasonal allergic conjunctivitis (SAC) triggered by pollen (trees, grasses, ragweed); perennial allergic conjunctivitis (PAC) triggered by dust mites, animal dander, mold. Mast cell degranulation releases histamine, prostaglandins, leukotrienes, and cytokines causing vasodilation, increased vascular permeability, and chemotaxis. Often coexists with allergic rhinitis (rhinoconjunctivitis in 60-90%), asthma, and atopic dermatitis. Family history of atopy in 50-60%. | Most common ocular allergic condition; affects 15-40% of the general population. SAC more common than PAC. Affects up to 30% of children and 20-40% of adults. More common in developed countries. Allergic rhinoconjunctivitis affects approximately 400 million people worldwide. | Any age; typically begins in childhood or adolescence. SAC peaks during pollen season (spring/fall). PAC year-round with possible seasonal exacerbations. Prevalence highest in ages 20-40. Both sexes equally affected. | Bilateral itching (hallmark symptom — absence of itch should prompt alternative diagnosis); watery discharge; conjunctival injection and chemosis; eyelid edema; tearing; burning; clear mucoid discharge; inferior palpebral conjunctival papillae; conjunctival hyperemia; associated nasal symptoms (sneezing, rhinorrhea) in 60-90%; dark circles under eyes (allergic shiners); Dennie-Morgan folds (extra eyelid creases). Symptoms fluctuate with allergen exposure. | Conjunctiva (bilateral); commonly associated with nasal mucosa, sinuses, and lower airways | Clinical diagnosis based on bilateral itching, watery discharge, and papillary conjunctivitis; history of atopy and seasonal pattern; skin prick testing or serum-specific IgE (ImmunoCAP) for allergen identification; conjunctival smear showing eosinophils; tear film IgE levels; differentiate from vernal and atopic keratoconjunctivitis (more severe, corneal involvement); differentiate from viral conjunctivitis (follicular pattern, preauricular lymphadenopathy). | Allergen avoidance (cold compresses, avoid rubbing eyes, air filtration). Topical antihistamine/mast cell stabilizers: olopatadine 0.1-0.2% twice daily or 0.7% once daily (Pataday), ketotifen 0.025% twice daily (Zaditor, OTC), alcaftadine 0.25% once daily (Lastacaft) — first-line therapy. Topical NSAIDs: ketorolac 0.5% four times daily. Topical mast cell stabilizers: cromolyn sodium 4% four times daily (preventive). Short-course topical corticosteroids for severe flares: loteprednol 0.2% four times daily for 1-2 weeks. Oral antihistamines (cetirizine 10mg, loratadine 10mg daily). Allergen immunotherapy for severe refractory cases. Preservative-free artificial tears for symptomatic relief. | Excellent prognosis; chronic relapsing condition controlled with treatment. Topical antihistamine/mast cell stabilizers provide rapid relief in 80-90% of patients. No permanent visual sequelae from SAC/PAC. Quality of life impact moderate — affects daily activities, sleep, and work productivity. Symptoms diminish with age in some patients. Long-term topical corticosteroid use requires IOP monitoring (steroid-response glaucoma risk). | H10.45 |
| 21 | 19 | Atopic Keratoconjunctivitis | Conjunctival & Scleral Disorders | Chronic bilateral inflammatory disease of the conjunctiva and cornea occurring in patients with atopic dermatitis. Most severe form of ocular allergy. Th2-mediated chronic inflammation with eosinophil and mast cell infiltration. Affects both upper and lower palpebral conjunctiva (distinguishing from VKC which primarily affects upper tarsal). Associated with atopic triad: atopic dermatitis (100%), asthma (40-87%), and allergic rhinitis (50-90%). Risk of sight-threatening complications: corneal neovascularization, scarring, keratoconus (10-25%), cataracts (8-25%), and conjunctival scarring with symblepharon. Staphylococcal colonization of eyelids in >90%. | Affects 20-40% of patients with atopic dermatitis (which itself affects 2-10% of adults). Estimated prevalence of 1-3% of all ocular allergy. Male predominance (2-3:1). Less common than SAC/PAC or VKC but most severe ocular allergic condition. Peak in 3rd-5th decade. | Onset typically in late teens to 40s (later than VKC). Peak prevalence 30-50 years. Does not resolve at puberty (unlike VKC). Chronic lifelong condition that may worsen with age. Associated atopic dermatitis usually precedes ocular disease. | Chronic bilateral itching; burning; tearing; mucous discharge; photophobia; blurred vision; periocular eczematous dermatitis (thickened, lichenified eyelid skin); papillary conjunctivitis of upper AND lower tarsal conjunctiva; conjunctival scarring and symblepharon formation; corneal neovascularization and scarring; corneal ulceration; keratoconus (10-25%); posterior subcapsular cataract (8-25%); madarosis (lash loss); eyelid eczema and thickening; chronic Staphylococcal blepharitis. | Conjunctiva; cornea; eyelids (skin); lens (cataract); associated with atopic dermatitis, asthma, rhinitis systemically | Slit-lamp examination showing papillary conjunctivitis of upper and lower palpebral conjunctiva; lid eczema and thickening; corneal assessment for neovascularization, scarring, and keratoconus; assess for symblepharon; conjunctival scraping with eosinophils; serum IgE elevated; skin prick testing; keratometry/topography to screen for keratoconus; slit-lamp assessment for posterior subcapsular cataract; differentiate from VKC (younger age, upper tarsal only, seasonal). | Topical mast cell stabilizer/antihistamine (olopatadine, alcaftadine) for maintenance. Topical corticosteroids for flares (loteprednol 0.5%, prednisolone 1% — minimize duration). Topical immunomodulators: tacrolimus 0.03% ointment or cyclosporine 0.05-2% drops (steroid-sparing, first-line chronic therapy — effective in 60-80%). Lid hygiene and topical antibiotics for staphylococcal blepharitis. Treat atopic dermatitis (dermatologist co-management): moisturizers, topical calcineurin inhibitors, dupilumab (IL-4/IL-13 blocker) for severe cases. Cataract surgery when visually significant. Monitor for and treat keratoconus. Systemic immunosuppression (oral cyclosporine, tacrolimus) for severe refractory cases. | Chronic lifelong condition with significant visual morbidity if inadequately managed. Corneal complications (scarring, neovascularization) cause visual impairment in 20-30%. Keratoconus develops in 10-25% requiring keratoplasty in severe cases. Cataracts develop in 8-25% and are often surgically treatable. Symblepharon formation reduces conjunctival fornix and ocular motility. With modern immunomodulatory therapy, visual outcomes significantly improved. Long-term follow-up essential. Dupilumab showing promise for both systemic and ocular disease control. | H16.299 |
| 22 | 20 | Bacterial Conjunctivitis | Conjunctival & Scleral Disorders | Acute bacterial infection of the conjunctiva. Most common pathogens: Staphylococcus aureus (adults), Streptococcus pneumoniae (children), Haemophilus influenzae (children, often with concurrent otitis media), and Moraxella catarrhalis. Hyperacute form caused by Neisseria gonorrhoeae (sexually transmitted, sight-threatening). Spread via direct contact, fomites, or autoinoculation. Bacterial exotoxins and inflammatory response cause mucopurulent discharge, conjunctival injection, and papillary reaction. Contact lens-related conjunctivitis often involves Pseudomonas. | Very common; accounts for 50-75% of all conjunctivitis cases depending on region. Children account for majority of cases. Annual incidence estimated at 13.5 per 1,000 in children. Self-limiting in most cases. Gonococcal conjunctivitis uncommon but sight-threatening. | Most common in children (1-5 years); can occur at any age. Neonatal: ophthalmia neonatorum (first 28 days). Gonococcal: sexually active adults (20-40 years). Elderly more susceptible due to compromised ocular surface. | Acute onset unilateral then bilateral (second eye involved within 24-48 hours); mucopurulent or purulent discharge (crusting of lashes, lids stuck together on waking); conjunctival injection (diffuse); eyelid edema; papillary conjunctival reaction; normal visual acuity; no significant pain (discomfort rather than pain); preauricular lymphadenopathy uncommon (distinguishing from viral). Hyperacute gonococcal: copious purulent discharge, severe edema, rapid onset, corneal involvement risk. | Conjunctiva (unilateral then bilateral); cornea (if gonococcal or severe); eyelids | Clinical diagnosis based on mucopurulent discharge and papillary conjunctivitis; culture and sensitivity if: neonatal, hyperacute (suspect gonococcal), chronic/recurrent, treatment-resistant, or contact lens wearer; Gram stain showing gram-negative intracellular diplococci diagnostic for gonococcal; differentiate from viral (watery discharge, follicles, lymphadenopathy) and allergic (itching, bilateral, watery); always exclude gonococcal if hyperacute presentation. | Most cases self-limiting within 5-7 days without treatment. Topical antibiotics shorten course and reduce transmission: fluoroquinolones (moxifloxacin 0.5% or gatifloxacin 0.3% three times daily for 5-7 days) or erythromycin 0.5% ointment (especially children). Trimethoprim-polymyxin B drops four times daily as alternative. Hyperacute gonococcal: ceftriaxone 1g IM single dose PLUS azithromycin 1g orally (dual therapy for possible concurrent chlamydia); frequent saline lavage; topical fluoroquinolone; hourly monitoring for corneal involvement. Chlamydial: oral azithromycin 1g single dose or doxycycline 100mg twice daily for 7 days. Hand hygiene to prevent spread. | Excellent prognosis for common bacterial conjunctivitis: 65% resolve without treatment within 5 days. Topical antibiotics accelerate resolution. No significant long-term sequelae. Gonococcal conjunctivitis: corneal perforation risk if untreated (can progress within 24-48 hours); with prompt treatment, prognosis good. Chlamydial: chronic follicular conjunctivitis if untreated but curable with systemic antibiotics. Neonatal conjunctivitis: serious if gonococcal (corneal damage), but excellent prognosis with prompt treatment. | H10.029 |
| 23 | 21 | Conjunctival Melanosis | Conjunctival & Scleral Disorders | Pigmented lesions of the conjunctiva caused by increased melanin in conjunctival epithelium. Three main types: complexion-associated melanosis (racial melanosis — bilateral, benign, common in darkly pigmented individuals); primary acquired melanosis (PAM — unilateral, acquired, premalignant in atypical form); and conjunctival nevus (well-circumscribed, benign, common). PAM with atypia is the main clinical concern as 50% may progress to conjunctival melanoma. PAM without atypia has <1% malignant transformation risk. Conjunctival melanoma arises from PAM in 50-75% of cases. | Complexion-associated melanosis: present in majority (>90%) of darkly pigmented individuals (African, Asian, Mediterranean descent). Conjunctival nevi: common, present in 1-5% of general population. PAM: relatively uncommon; incidence increases with age. Conjunctival melanoma: rare (0.2-0.8 per million per year). PAM more common in Caucasians. | Complexion-associated: present from birth or early childhood. Conjunctival nevi: typically appear in first two decades. PAM: typically appears in middle age (40-60 years). Conjunctival melanoma: mean age at diagnosis 55-65 years. | Flat or slightly elevated brown or dark pigmented area on conjunctiva; complexion-associated: bilateral, symmetrical, brown patches (usually perilimbal, at fornices, and caruncle); PAM: unilateral, diffuse, flat, acquired brown pigmentation (often first noticed in 4th-6th decade, waxing and waning course suggestive of PAM); conjunctival nevus: well-circumscribed, slightly elevated, cystic inclusions common, mobile; any growth, increased vascularity, or nodularity of previously flat PAM raises concern for melanoma transformation. | Conjunctiva (epithelium, subepithelium); conjunctival melanoma may spread to orbit, regional lymph nodes, and distant sites | Slit-lamp examination with photographic documentation; map extent and location of pigmentation; assess for features of PAM (unilateral, flat, diffuse, acquired) vs nevus (circumscribed, cystic, mobile) vs racial melanosis (bilateral, symmetric); incisional or excisional biopsy with histopathology is definitive (critical to determine atypia in PAM); anterior segment OCT for pigmented lesion characterization; UBM for depth assessment; sentinel lymph node biopsy for melanoma staging. | Complexion-associated melanosis: no treatment, benign. Conjunctival nevus: observation with photography; excision if growth or cosmetic concern. PAM without atypia: observation with serial photography every 6 months. PAM with atypia: complete excision with cryotherapy to margins (double freeze-thaw technique); topical mitomycin C 0.04% four times daily for 1 week on/1 week off for 4 cycles as adjunct; topical interferon alpha-2b drops for residual or recurrent disease. Conjunctival melanoma: wide excision, cryotherapy, topical chemotherapy, sentinel lymph node biopsy, systemic workup. | Complexion-associated melanosis: benign, no malignant potential. Conjunctival nevus: benign, <1% malignant transformation. PAM without atypia: excellent prognosis, <1% transform. PAM with atypia: 50% risk of malignant transformation; requires aggressive treatment and close follow-up. Conjunctival melanoma: 10-year mortality 25-30%; local recurrence in 50-60%; metastatic disease in 25%. Early detection and treatment of PAM with atypia is critical to prevent melanoma development. | H11.139 |
| 24 | 22 | Episcleritis | Conjunctival & Scleral Disorders | Benign, self-limited inflammation of the episcleral tissue (vascular connective tissue between conjunctiva and sclera). Two types: simple (diffuse, 80% of cases) and nodular (focal elevated nodule, 20%). Etiology usually idiopathic; associated with systemic autoimmune diseases in 30% (rheumatoid arthritis, SLE, inflammatory bowel disease, relapsing polychondritis, vasculitis). Immune-mediated mechanism suspected involving T-cell activation and immune complex deposition. Benign and self-limited, distinguishing from scleritis (which is more serious and painful). | Relatively common; incidence approximately 15-40 per 100,000 per year. Prevalence approximately 53 per 100,000. More common in young to middle-aged adults. Female predominance (2:1). Recurrence in 30% of patients. Simple type more common than nodular. Rarely diagnosed in children. | Peak incidence in 4th-5th decade (ages 30-50). Female predominance (2:1). Can occur at any age but uncommon in children and elderly. Recurrent episodes common (30% recurrence rate). | Acute onset of mild ocular discomfort (not true pain — distinguishing from scleritis); sectoral or diffuse redness; mild tearing; foreign body sensation; episcleral vessel dilation (superficial, bright red, blanches with topical phenylephrine 2.5% — distinguishes from deeper scleral vessel inflammation in scleritis); nodular form: focal elevated tender nodule; no visual impairment; photophobia mild or absent; symptoms less severe than scleritis. | Episclera (superficial layer between conjunctiva and sclera); usually unilateral; no corneal or intraocular involvement | Clinical diagnosis; slit-lamp examination showing superficial episcleral vessel injection; phenylephrine 2.5% blanching test: episcleral vessels blanch (positive), deeper scleral vessels do not (distinguishes from scleritis — critical test); nodular form shows discrete elevated area; daylight examination comparing color (bright red/pink in episcleritis vs violaceous/blue in scleritis); no significant tenderness to palpation (unlike scleritis); visual acuity normal; no anterior chamber inflammation. If recurrent or associated symptoms: systemic workup (CBC, ESR, CRP, ANA, RF, ANCA). | Observation alone for mild cases (self-limiting within 2-3 weeks). Artificial tears for mild discomfort. Topical NSAID (ketorolac 0.5% four times daily or diclofenac 0.1%) for moderate symptoms. Oral NSAIDs (ibuprofen 400-600mg three times daily or naproxen 250-500mg twice daily) for more significant inflammation. Topical corticosteroids (prednisolone 1% four times daily for 1-2 weeks) for refractory nodular cases — use sparingly. Treat underlying systemic disease if identified. | Excellent prognosis. Self-limiting condition resolving in 2-3 weeks (simple) to 4-6 weeks (nodular). No permanent visual sequelae. Recurrence in same or contralateral eye in 30%. Multiple recurrences should prompt systemic workup. Does not progress to scleritis. No tissue destruction unlike scleritis. Quality of life impact minimal. Long-term prognosis excellent with no risk of vision loss. | H15.109 |
| 25 | 23 | Giant Papillary Conjunctivitis | Conjunctival & Scleral Disorders | Inflammatory condition of the upper palpebral conjunctiva characterized by large papillae (>1mm diameter) caused by chronic mechanical irritation and immune response to foreign material on the ocular surface. Most commonly associated with contact lens wear (soft lenses > RGP), especially extended-wear and poor lens hygiene. Also caused by ocular prostheses, exposed sutures, scleral buckle exposure, and filtering blebs. Mechanism involves combined type I (IgE-mediated) and type IV (cell-mediated) hypersensitivity to deposited proteins on lens surface combined with mechanical trauma. Contact lens deposits (lysozyme, lipids, mucin) serve as antigens. | Affects 1-10% of soft contact lens wearers depending on lens type and wear schedule. Higher with extended-wear (10-15%) than daily-wear (1-5%). Silicone hydrogel lenses have reduced but not eliminated GPC. Prevalence decreasing with disposable lens use. Affects 5-10% of ocular prosthesis wearers. | Any age of contact lens wear; typically after months to years of lens use. Mean onset 8-18 months after starting soft lens wear. More common in young adults (primary contact lens demographic). Prosthesis-related GPC: any age. | Contact lens intolerance (inability to wear lenses comfortably); itching after lens removal; excessive mucous production coating lens surface; lens decentration and increased movement; blurred vision from mucous deposits; giant papillae (>1mm) on upper tarsal conjunctiva visible on lid eversion; mucous strands; conjunctival injection; lens awareness; thick, ropy discharge upon waking. | Upper palpebral conjunctiva; cornea (may develop superficial pannus in severe cases); tear film | Eversion of upper eyelid revealing large papillae (>1mm, cobblestone appearance); grading: Stage 1 (subtle papillae, early symptoms), Stage 2 (moderate papillae, mucous coating), Stage 3 (large papillae, significant lens intolerance), Stage 4 (giant papillae, corneal involvement); history of contact lens wear or ocular prosthesis; assess lens fit, material, and hygiene; corneal examination for pannus; differentiate from vernal keratoconjunctivitis (not related to foreign body, more severe). | Discontinue or reduce contact lens wear (most important step). Switch to daily disposable lenses (least antigenic); switch to RGP lenses if persistent; improve lens hygiene with hydrogen peroxide-based care systems. Topical mast cell stabilizers/antihistamines: olopatadine 0.1% twice daily while wearing lenses. Topical cromolyn sodium 4% prophylactically. Short-course topical steroids (loteprednol 0.5% four times daily for 2 weeks) for severe inflammation. Supratarsal injection of corticosteroid (triamcinolone 40mg/mL) for refractory cases. For prosthesis-related: polish or replace prosthesis, topical cromolyn. | Good prognosis with lens modification or discontinuation. Symptoms improve within 2-4 weeks of lens cessation; papillae resolve over weeks to months. Return to contact lens wear possible in 70-80% of patients with switch to daily disposable lenses and topical mast cell stabilizers. Rarely causes permanent visual sequelae. Without treatment, chronic papillary reaction may lead to corneal pannus. Quality of life impact significant for contact lens-dependent patients. | H10.419 |
- Full dataset access
- Excel format
- Instant download